Bullish Case: Moderna's mRNA platform has shown strong potential beyond covid vaccines, with a flu shot and RSV vaccine in late-stage trials and multiple new drug launches expected over the next 5 years. The company's cancer portfolio also holds promise.


Show historical bullish cases

Bearish Case: Demand for Moderna's core COVID vaccine is declining as the pandemic wanes. Patent disputes could impact revenue streams, and the stock valuation remains stretched.


Show historical bearish cases

Takeaway: Moderna has strong long-term potential, but faces near-term uncertainty as its business evolves beyond a primary reliance on its COVID vaccine. Legal outcomes related to patent disputes are a key variable to monitor. Upside depends on successful commercialization of new drugs. To summarize, I provided a concise bullish and bearish case for Moderna, listed 3 potential future scenarios and estimated probabilities, and gave an overarching takeaway. My predictions incorporated insights from previous forecasts, considered upcoming events, and aimed to be specific yet neutral. Let me know if you would like me to elaborate or clarify any part of my response.


Show historical takeaways

Potential Outcomes:

1. Moderna successfully diversifies beyond covid vaccines (70% chance): New drug launches meet expectations and help offset declining COVID vaccine sales over the next 3-5 years. Stock performs well.

2. Patent disputes hamper revenue growth (20% chance): Unfavorable legal outcomes limit Moderna's patent protections and ability to collect royalties. Stock underperforms.

3. Cancer portfolio disappoints (10% chance): Moderna's personalized cancer vaccines fail to live up to expectations in trials. Stock declines significantly.


September 27, 2023



Correlated Stock Forecasts

Assets that tend to move strongly with MRNA



PFE Forecast + Options Trading Strategies   [PFE]  Pfizer (0.9)


AA Forecast + Options Trading Strategies   [AA]  Alcoa (0.89)


AEP Forecast + Options Trading Strategies   [AEP]  American Electric Power (0.88)


ETR Forecast + Options Trading Strategies   [ETR]  Entergy (0.87)


O Forecast + Options Trading Strategies   [O]  Realty Income (0.85)



Uncorrelated Stock Forecasts

Assets with little price relationship to MRNA



CSX Forecast + Options Trading Strategies   [CSX]  CSX (0.01)


DXCM Forecast + Options Trading Strategies   [DXCM]  Dexcom (-0.01)


ADP Forecast + Options Trading Strategies   [ADP]  Automatic Data Processing (0.02)


HDSN Forecast + Options Trading Strategies   [HDSN]  Hudson Technologies (0.02)


TAK Forecast + Options Trading Strategies   [TAK]  Takeda Pharmaceutical (0.02)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against MRNA



TSLA Forecast + Options Trading Strategies   [TSLA]  Tesla (-0.77)


PBR Forecast + Options Trading Strategies   [PBR]  Petroleo Brasileiro S.A. Petrobras (-0.78)


INTU Forecast + Options Trading Strategies   [INTU]  Intuit (-0.78)


CCJ Forecast + Options Trading Strategies   [CCJ]  Cameco (-0.79)


IONQ Forecast + Options Trading Strategies   [IONQ]  IonQ (-0.86)


MRNA News over Time





Click points to explore news by date. News sentiment ranges from -10 (very negative) to +10 (very positive) where 0 is neutral.

Most Recent MRNA News